XT
NBIX icon

XTX Topco’s Neurocrine Biosciences NBIX Stock Holding History

XTX Topco’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,775
Closed -$1.67M – 4178
2025
Q4 		$1.67M Buy
11,775
+9,013
+326% +$1.31M 0.04% 683
2025
Q3 		$388K Sell
2,762
-22,255
-89% -$3.02M 0.02% 1290
2025
Q2 		$3.14M Buy
25,017
+5,463
+28% +$626K 0.13% 177
2025
Q1 		$2.16M Buy
19,554
+12,688
+185% +$1.61M 0.11% 233
2024
Q4 		$937K Sell
6,866
-1,799
-21% -$223K 0.08% 339
2024
Q3 		$998K Buy
8,665
+5,322
+159% +$730K 0.07% 429
2024
Q2 		$460K Sell
3,343
-4,464
-57% -$612K 0.04% 698
2024
Q1 		$1.08M Buy
7,807
+3,342
+75% +$456K 0.15% 139
2023
Q4 		$588K Buy
4,465
+1,200
+37% +$138K 0.13% 179
2023
Q3 		$367K Sell
3,265
-5,243
-62% -$552K 0.06% 593
2023
Q2 		$802K Buy
8,508
+4,080
+92% +$399K 0.14% 153
2023
Q1 		$448K Buy
4,428
+19
+0.4% +$1.98K 0.09% 363
2022
Q4 		$527K Buy
4,409
+1,402
+47% +$164K 0.11% 276
2022
Q3 		$319K Sell
3,007
-507
-14% -$51.4K 0.08% 464
2022
Q2 		$343K Buy
+3,514
New +$324K 0.14% 228

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco's NBIX Position: Q1 2026 in Review

XTX Topco sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 11,775 shares — an estimated $1.67M sold.

XTX Topco first reported a position in NBIX in Q2 2022 and held it in 15 quarters. The position peaked at $3.14M in Q2 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • XTX Topco reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 11,775 Neurocrine Biosciences shares in Q1 2026, an estimated $1.67M.
  • XTX Topco first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 15 quarters.
  • XTX Topco's Neurocrine Biosciences position peaked at $3.14M in Q2 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.